trending Market Intelligence /marketintelligence/en/news-insights/trending/p5nctoifovqrempgf_qr-q2 content esgSubNav
In This List

Nordic Nanovector's lymphoma drug gets US FDA fast-track status

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Nordic Nanovector's lymphoma drug gets US FDA fast-track status

Nordic Nanovector ASA said the U.S. Food and Drug Administration granted fast-track status to its blood cancer drug Betalutin.

The designation covers the drug, also known as 177Lu-lilotomab satetraxetan, as a treatment for patients who received at least two earlier systemic therapies for a type of hard-to-treat blood cancer that had relapsed, the Oslo-based biopharmaceutical company said.

The designation is based on safety and efficacy data from an early stage trial for non-Hodgkin's lymphoma, Nordic Nanovector Chief Medical Officer Lisa Rojkjaer said in a news release.

The FDA's fast-track process is designed to facilitate development and expedite the review of drugs used to treat serious conditions and fill an unmet medical need. The status also provides eligibility for accelerated approval and priority review, given the appropriate criteria are met.